VERWENDUNG VON SCHILDDRÜSEN-BETA-AGONISTEN

European patent · EP3445372 · In force

Register entry

Publication number
EP3445372
Application number
EP17786795
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
Apr 24, 2017
Published
Feb 27, 2019
Granted
Feb 25, 2026
Protection ends at the latest
Apr 23, 2037
Next annual fee due
Apr 30, 2027
IPC classes
A61K 31/662 (2006.01)
A61K 31/665 (2006.01)
A61P 5/14 (2006.01)
Priority
US 201662326431 P 22.04.2016
PCT application
PCT/US2017/029102 24.04.2017
PCT publication
WO2017/185083 26.10.2017
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. May 1, 2026

    Change

    Published in Swissreg on 01.05.2026

  2. Apr 20, 2026

    Agent entered

    Representative
    VALIPAT, c/o BOVARD LTD, Optingenstrasse 16, 3013 Bern

    Published in Swissreg on 20.04.2026

  3. Feb 25, 2026

    Granted

    Specification status
    Non-published patent application → Granted patent
    Status of protective title
    Initiated → Active

    Published in Swissreg on 25.02.2026

Parties

Holder

Viking Therapeutics, Inc.

12340 El Camino Real Suite 250, San Diego, CA 92130, US

Agent

VALIPAT c/o BOVARD LTD

Optingenstrasse 16, 3013 Bern

Inventor

LIAN, Brian

Rancho Santa Fe CA 92067, US

HANLEY, Rochelle

Ann Arbor MI 48105, US

DINERMAN, Misha

Cincinnati OH 45208, US

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.